Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms

Michael Riedel, Norbert Müller, Martin Strassnig, Ilja Spellmann, Rolf R. Engel, Richard Musil, Sandra Dehning, Anette Douhet, Markus J. Schwarz, Hans Jürgen Möller

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

Atypical antipsychotics are generally thought to be more effective than conventional agents in treating the negative symptoms of schizophrenia; however, there have been few direct comparisons among atypicals. We therefore investigated risperidone and quetiapine with respect to their efficacy against negative symptoms in a 12-week, double-blind, comparative pilot study involving 44 patients with schizophrenia with predominantly negative symptoms, as defined by Positive and Negative Syndrome Scale (PANSS) scores. Other efficacy measures included the Scale for the Assessment of Negative Symptoms (SANS) and the Clinical Global Impression (CGI) rating scale. Antipsychotic tolerability was assessed using the Simpson-Angus Scale (SAS) and various laboratory measures. Mean doses were 589.7 mg/ day quetiapine and 4.9 mg/day risperidone (observed cases). Both antipsychotics produced significant decreases in PANSS total, positive and negative scores, and SANS scores. Patients receiving risperidone were significantly more likely to experience extrapyramidal symptoms (EPS) [p < 0.05], or to require anticholinergic medication (p < 0.05), and had significantly higher prolactin levels (p < 0.001) than quetiapine-treated patients. In conclusion, there is no significant difference in efficacy between quetiapine and risperidone in alleviating the negative symptoms of schizophrenia. Quetiapine is also well tolerated, with a lower incidence of EPS and prolactin increase than risperidone.

Original languageEnglish (US)
Pages (from-to)432-437
Number of pages6
JournalEuropean Archives of Psychiatry and Clinical Neuroscience
Volume255
Issue number6
DOIs
StatePublished - Dec 1 2005

    Fingerprint

Keywords

  • Atypical antipsychotic
  • Negative symptoms
  • Quetiapine
  • Risperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuropsychology and Physiological Psychology
  • Clinical Neurology

Cite this

Riedel, M., Müller, N., Strassnig, M., Spellmann, I., Engel, R. R., Musil, R., Dehning, S., Douhet, A., Schwarz, M. J., & Möller, H. J. (2005). Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience, 255(6), 432-437. https://doi.org/10.1007/s00406-005-0622-6